News

Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke...

A large-scale analysis assessing the real-world risk of venous thromboembolism (VTE) in chemotherapy patients...

The U.S. Food and Drug Administration (FDA)’s Cardiovascular and Renal Drugs Advisory Committee recommended approval of vorapaxar, Merck’s investigational ...

The U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee voted against the approval of the use of oral anticoagulant Xarelto (rivaroxaban) to reduce the risk...

A clinical trial found that Xa inhibitor edoxaban met the primary efficacy endpoint of non-inferiority compared to warfarin for the prevention of stroke or systemic embolic events (SEE) in...

acc pharmaceuticals renal denervation heart valve repair antiplatelet therapy

Clinical trials for a promising new class of cholesterol-lowering medications, a long-awaited repair of the Medicare formula for paying physicians, the Affordable Care Act, new technology and the...

CSL Behring announced that Kcentra (Prothrombin Complex Concentrate [Human]) has received U.S. Food and Drug Administration (FDA) approval for an expanded indication — urgent reversal of acquired...

clinical trial study antiplatelet thomas jefferson cath function monitors

Thomas Jefferson University researchers discovered that the formation of blood clots follows a different molecular route in African Americans versus European Americans, providing a new...

Combining genetic data with clinical information to determine the initial dosage of the blood thinner warfarin, used to prevent blood clots in the circulatory system, was no more effective in...

antiplatelet therapy clinical trial blood test platelet function corgenix

study conducted in Ireland found that aspirin does not adequately protect 20 percent of patients with...

Professional cardiovascular societies and many working cardiologists question the U.S. Food and Drug Administration’s (FDA’s) recent recommendation that patients undergo genetic testing before...

A new study demonstrated that some patients may not need to receive prolonged anti-clotting therapy after drug-...

cath lab clinical trial study pharmaceuticals antiplatelet therapy arctic

Patients who do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual ...

xience prime xpedition V antiplatelet stents eluting clinical trial study cath

Abbott announced it plans to initiate a randomized, controlled trial in the United States to evaluate the use...

PDI, Inc. and Transgenomic, Inc. announced the signing of a U.S. collaboration agreement to commercialize CardioPredict, a molecular diagnostic test developed by Transgenomic. CardioPredict is a...

Icahn School of Medicine at Mount Sinai PARIS Study Antiplatelet Therapy PCI

Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) study findings at the ESC...

Aggredyne Inc., has received ISO 13485 certification for its quality control program related to the manufacture of the AggreGuide family of platelet function analyzers.

Decision Resources forecasts that Bayer/Janssen's Xarelto will be the sales-leading therapy among the novel oral anticoagulants in the combined venous thromboembolism (VTE) markets. Xarelto...